Clinical Trials and Research
The Department of Ophthalmology currently participates in several clinical trials involving new therapeutic and diagnostic methods for various diseases, including:
SCOPE
A Study of Disease Progression in Genetically Defined Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
HORIZON
A phase II, open-label, outcomes-assessor masked, multicenter, randomized, controlled study to evaluate the safety and efficacy of two doses of GT005 administered as a single sub retinal injection in subjects with geographic atrophy secondary to dry age-related macular degeneration.
EXPLORE
A Phase 2, outcomes assessor-masked, multicenter, randomized study to evaluate the safety and efficacy of two doses of GT005 administered as a single sub retinal injection in subjects with geographic atrophy secondary to age-related macular degeneration.
4D Therapeutics
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males with X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene.
STARGAZER
A Phase 2b/3 Randomized, Double-Masked, Placebo Controlled Study to Evaluate the Safety and Efficacy of STG-001 in Subjects with Stargardt Disease (STGD1) Caused by Autosomal Recessive Mutation in ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene.
SOLSTICE
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of Retinal Gene Therapy in Subjects with Choroideremia Previously Treated with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) and in Subjects with X-Linked Retinitis Pigmentosa Previously Treated with Adeno-Associated Viral Vector Encoding RPGR(AAV8-RPGR) in an Antecedent Study.
MAPS
Structural and Functional Progression of Glaucomatous Damage to the Macula.
Vitamin B3
Nutritional supplements and performance during visual field testing.
Pigmentary Glaucoma
Determining Genetic Causality of Pigmentary Glaucoma.
BASICHR0031
Basic human research study of novel glaucoma endpoints and identification of optimal patient populations for neuroprotection trials.
AURA
A Phase 2 trial of AU-011 via suprachoroidal administration with a dose escalation phase (open-label, ascending single and repeat dose) and a randomized, masked dose expansion phase designed to evaluate the safety and efficacy of AU-011 in subjects with primary indeterminate lesions and small choroidal melanoma.